Skip to main content
ABL Diagnostics logo

ABL Diagnostics — Investor Relations & Filings

Ticker · ABLD ISIN · FR0000063034 LEI · 9695002UO0UHM0VKRH38 PA Manufacturing
Open in API
Filings indexed 128 across all filing types
Latest filing 2026-06-12 Regulatory Filings
Country FR France
Listing PA ABLD

About ABL Diagnostics

https://www.ablsa.com

ABL Diagnostics is a molecular diagnostics company that develops and commercializes solutions for the diagnosis and management of infectious diseases. The company's offerings include in-vitro diagnostic (IVD) medical devices, PCR-based assays such as the UltraGene product line, and integrated software for data analysis and laboratory automation. ABL Diagnostics also provides the Nadis® electronic medical record (EMR) system for clinical data management. The company specializes in genotyping and sequencing technologies, with a primary focus on monitoring drug resistance in viral infections like HIV and viral hepatitis.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Regulatory Filings Classification · 75% confidence The document is a press release announcing the signing of a multi‐year service contract with a pharmaceutical customer, detailing the contract’s value, scope, and strategic context. It does not provide financial statements or serve as an earnings release, investor presentation, or regulatory certification. It is a general corporate announcement that does not fit any of the more specific categories like earnings release (ER), capital financing (CAP), M&A, or share issues. Therefore, it falls under the residual category of general regulatory announcements (Regulatory Filings).
2026-06-12 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 52% confidence The provided text is a press release announcing a multi-year service contract worth up to €2.7 million with a pharmaceutical laboratory, including background on the agreement, expected revenue recognition, and company information. It is not a financial report (annual, interim, earnings, audit), not a management changes notice, not a dividend or share transaction, and does not contain actual financial statements. It also is not an investor presentation or proxy material. Therefore, it falls into the residual category for miscellaneous regulatory announcements that do not fit specific classifications: Regulatory Filings (RNS).
2026-06-12 French
Inside Information / Operations of the issuer (acquisitions, sales...)
M&A Activity Classification · 85% confidence The document is a press release announcing that ABL Diagnostics has submitted a takeover bid to acquire Texcell France, referencing the French Commercial Code and insolvency proceedings. It is an announcement of M&A activity (takeover bid), not a full regulatory filing form or annual/interim report. Therefore it fits the M&A Activity category.
2026-06-10 English
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
M&A Activity Classification · 91% confidence The document is a regulated press release announcing that ABL Diagnostics has filed a takeover offer (“offre de reprise”) for Texcell France. It contains no financial statements or detailed performance data, but clearly describes an M&A transaction proposal. This matches the “Announcements and documents related to merger proposals or takeover bids” definition for M&A Activity (Code: TAR).
2026-06-10 French
Modalités de mise à disposition des documents préparatoires à l'AG
Declaration of Voting Results & Voting Rights Announcements Classification · 91% confidence The document is a formal announcement under French commerce and AMF regulations providing the total number of shares and voting rights of the company as of a specified date. It specifically relates to the number of voting rights and share capital, which corresponds to Declaration of Voting Results & Voting Rights Announcements (Code DVA). It is not an AGM presentation or a financial report but a statutory voting rights notice.
2026-06-10 French
Terms of availability of the preparatory documents for the GM
Regulatory Filings Classification · 85% confidence The document is a standalone regulatory announcement under French Commercial Code articles L. 233-8 and AMF regulation 223-16, disclosing the total number of shares and voting rights. It does not contain vote results from a shareholder meeting, nor is it presenting a full financial report, management discussion, dividend notice, or capital change. It is a miscellaneous compliance filing that does not fit other specific categories, so it falls under Regulatory Filings (RNS).
2026-06-10 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.